How Becerra and Hilton differ on California health care

This article tries to be unbiased and compares Xavier Becerra (Democrat, former U.S. HHS Secretary, California AG, and Congressman) and Steve Hilton (Republican, former Fox News host, British-born American conservative political commentator, author, entrepreneur, and former adviser) contrasting approaches to health care.

Becerra emphasizes government-led expansion of access, protections against federal rollbacks, cost controls via regulation and purchasing power, and a long-term vision for universal coverage. Hilton focuses on reducing government spending (especially on undocumented immigrants), combating fraud and waste, increasing competition and deregulation, and prioritizing affordability for citizens and legal residents.

Xavier Becerra’s ideas and strategies

Becerra has a long record as a proponent of expansive government involvement in health care:

Universal access and single-payer aspirations: He has long supported single-payer and Medicare for All-style systems as a goal (“health care is a human right”) and co-sponsored related legislation in Congress. In the 2026 governor’s race, he has moderated this, stressing “immediate wins” and incremental reforms while still aiming to build toward a universal single-payer CalCare system that prioritizes people over profits. He acknowledges practical barriers (for example, under a Trump administration) but maintains support in principle.
Protect and expand coverage: Defend Medi-Cal (California’s Medicaid), guarantee access regardless of income, zip code, or immigration status, and shield against federal cuts. As HHS Secretary and AG, he fought Trump-era efforts to undermine the ACA, sued pharmaceutical companies, and pushed for lower drug prices and expanded protections.
Cost reduction and prevention: Lower premiums, out-of-pocket costs, and drug prices using state tools (purchasing power, regulation, enforcement). Shift toward primary and preventive care and wellness to reduce expensive ER visits. Invest in the health care workforce, especially in underserved areas.
Broader record: Championed ACA provisions, Medicare improvements, electronic health records, and equity-focused policies. As HHS Secretary, focused on pandemic response, behavioral and mental health, and reducing disparities.

Overall strategy: Defensive against federal threats, plus proactive state-level expansions and investments. Relies on government regulation, spending, and enforcement to achieve affordability and universality. Critics (including in the race) note past flip-flopping perceptions on single-payer timing and endorsements from groups like the California Medical Association.

Steve Hilton’s ideas and strategies

Hilton advocates market-oriented reforms, spending restraint, and citizen-first priorities as part of his “Califordable” agenda:

Cut spending on undocumented immigrants: A core proposal is ending or limiting full Medi-Cal coverage for undocumented individuals (estimated $20 billion per year in savings), redirecting funds to lower costs and improve access and wait times for working Californians and legal residents. In his Califordable campaign, he calls providing “free health care” to those here illegally “outrageous” while citizens struggle.
Competition, deregulation, and efficiency: Increase competition in insurance and provider markets, stop consolidation, use technology and deregulation to lower costs. Combat fraud, waste, and abuse in programs like Medi-Cal (for example, fake billing, poor oversight). He proposes a “Cal DOGE” effort to root out inefficiencies.
Critique of government-run systems: Opposes single-payer as impractical and costly; draws from U.K. NHS experience (where he says it “nearly killed” him as a patient) to argue against expansive government models, favoring targeted, limited Medicaid-style programs.
Broader affordability ties: Links health care to tax cuts (for example, no state income tax on the first $100,000), overall spending restraint, and addressing root drivers like immigration and bureaucracy.

Overall strategy: Reduce government scope and spending on non-citizens, enhance market competition, and enforce accountability to drive down costs organically. Emphasizes scrutiny after years of one-party Democratic rule in California. He has clashed directly with Becerra on these points in debates.

Key comparisons

Philosophy: Becerra views health care as a right best secured through government expansion and protections (universal, inclusive of immigration status). Hilton sees it as a service strained by overreach, best fixed by limiting eligibility, cutting waste, and enabling markets.
Coverage priorities: Becerra favors broad protections, including for undocumented residents. Hilton prioritizes citizens and legal residents and would restrict non-citizen benefits.
Cost control: Becerra leans on regulation, prevention, and state power against pharma and insurers. Hilton leans on spending cuts (especially Medi-Cal for immigrants), competition, and anti-fraud.
Single-payer and government role: Becerra supports it in principle (with pragmatic caveats). Hilton strongly opposes it, citing failures like the NHS.
Implementation: Becerra leverages executive action, lawsuits, and investments. Hilton emphasizes budget reforms, deregulation, and new oversight mechanisms.

These positions align with their parties and the 2026 California governor’s race context, where health care affordability, Medi-Cal sustainability, and federal-state tensions (under Trump) are major issues. Becerra draws on extensive executive experience; Hilton on outsider critique and a business and competition focus.

California’s health care system is strained by bureaucracy, misaligned incentives, and over-regulation:

Reimbursement and financial pressures: Medicare physician pay has fallen about 33 percent since 2001 (inflation-adjusted), while practice costs rose. Low Medi-Cal rates make serving many patients unsustainable, contributing to consolidation and reduced access.
Administrative burden: Prior authorization, step therapy, EHR documentation, and insurer hurdles consume about half of physicians’ time, delay care (leading to ER visits, disease progression, opioid reliance), drive burnout (top contributor per surveys), and increase systemic costs despite cost-control intent. Gold card programs (exempting high-performing providers) are proposed as a practical fix.
Pain management specifics: Overly restrictive policies harm chronic pain patients (millions affected) by limiting multimodal care, while failing to curb illicit drug crises. Workers’ comp litigation inflates costs dramatically (litigated claims cost two to three times more or higher).
Gubernatorial race and broader critique: The 2026 race lacks a serious health care plan addressing these root issues (prevention, relational care, tax and regulatory relief, malpractice reform, AI for bureaucracy). The status quo prioritizes bureaucracy and insurers over patients and providers.
System delays and administrative inefficiencies: One article details personal experiences with months-long waits for diagnostics, results, and follow-ups, even for an insider physician, exacerbated by prior authorization (PA) requirements. AMA data cited shows 94 percent of physicians report PA delays care, with measurable harms like disease progression and higher ER use. This “time theft” from abusive oversight diverts clinicians from care.
Medical board overreach and prosecutorial tactics: Multiple articles highlight an “accuse first, prove later” mindset, retroactive scrutiny of old records (for example, decade-old notes using outdated guidelines), reliance on unqualified or biased experts, prolonged investigations (averaging 1,000-plus days), and disproportionate penalties. This creates fear, defensive medicine, burnout, and physician exodus, especially in pain management. Reforms like SB 815 are deemed insufficient. Combined with high taxes (13.3 percent top rate) and living costs, this worsens shortages, especially in underserved areas.
Opioid policy hypocrisy: California imposes strict limits on legitimate pain prescriptions (hurting wildfire survivors and chronic pain patients, one in five adults) while funding extensive harm reduction (needles, pipes, test strips) for illicit users. MBC actions and retroactive enforcement are blamed for undertreatment, suicides, and failing to address street fentanyl (more than 80 percent of overdoses).
Broader impacts on patients and workforce: Overregulation weaponizes rules, stifles innovation, drives fellowship declines (for example, a 46 percent drop in pain medicine), worsens shortages (high taxes plus board tactics), and creates a “silent crisis” where pain patients lose access while doctors face financial ruin, lost contracts, and reputational damage. Bureaucracy prioritizes compliance and profit over patient-centered, individualized care.

Evaluation: These are practitioner perspectives grounded in clinical experience, data (for example, AMA surveys, WCRI studies, burnout reports), and calls for targeted reforms like MEI-tied updates, due process in boards, gold cards, and streamlined processes. Strengths include specificity on pain care and California realities. Potential limitations: focus on pain specialty (may not fully represent all fields) and an advocacy tone. They align with broader evidence on U.S. administrative waste (about 25 to 30 percent of spending) and physician flight from high-regulation states. They effectively illustrate unintended consequences of well-intentioned rules but maintain a strong pain-specialty lens. They add urgency by quantifying workforce attrition and patient harms beyond the prior set.

Comparison of Becerra vs. Hilton strategies

These observations, without being biased, drawn from clinical and operational perspectives, point to needs for targeted improvements: updating reimbursements, reducing unnecessary administrative hurdles, enhancing due process in oversight, promoting prevention and relational care, and addressing workforce sustainability. Proposed fixes include efficiency tools, streamlined regulations, and incentives that support providers and patients directly.

The perspectives underscore practical challenges in balancing access, cost, quality, and sustainability. Different strategies may address these through varying combinations of investment, regulation, competition, and oversight reform.

Deregulation and anti-bureaucracy: Articles decry prior auth and step therapy, board overreach, and administrative bloat. Hilton’s focus on cutting red tape, fraud and waste (for example, “Cal DOGE”), and enabling markets and competition directly addresses this. Gold cards, streamlined workers’ comp, and tax relief echo his affordability agenda. Becerra has criticized excessive prior auth as burdensome (for example, “pencil pusher” delays in Medi-Cal) and urged insurers to reduce it for specific treatments like medication-assisted therapy. As HHS Secretary, his department advanced federal prior auth reforms. However, his focus is on targeted streamlining and enforcement rather than broad elimination or gold card exemptions. He pairs this with stronger oversight.
Physician shortages and retention: High taxes, regulatory hostility, and low reimbursements driving exodus support Hilton’s citizen-first spending restraint (freeing resources for sustainable programs) and pro-competition stance. Becerra has a strong focus on workforce investment like loan repayment, housing aid, incentives for primary care and rural providers, and training pipelines. He has supported the Medical Board of California in enforcement actions (as AG) and backed discipline for issues like COVID misinformation. No prominent criticism of board overreach; emphasis is on protecting access via regulation and investment, not easing oversight.
Cost control via efficiency: Litigation costs, denial-rework cycles, and consolidation critiques favor market-oriented fixes over pure regulation and purchasing power. Hilton’s opposition to single-payer-style expansions matches warnings about unsustainable bureaucracy. Becerra prefers state purchasing power (CalRx expansion, drug negotiations), antitrust enforcement, and employer fees over pure market competition. He opposes heavy deregulation; historically a strong single-payer advocate (now more incremental due to politics). His focus is on equity, prevention, and countering federal cuts rather than cutting red tape broadly.
Weaponization of rules: The criticism of punitive boards and “weaponized” rules, time-wasting bureaucracy, and anti-competitive effects (physician flight, consolidation) directly bolster Hilton’s calls for deregulation, anti-fraud and efficiency measures (“Cal DOGE”), tax relief, and market competition. Hilton’s citizen-focused spending restraint and opposition to expansive government models address the documented exodus and access barriers. Becerra’s campaign platform includes explicit planks to streamline administrative oversight (eliminate duplicative requirements, modernize and consolidate rules, review outdated standards) and reduce Medi-Cal churn waste via automation. He also pledges fraud task forces (building on his AG prosecutions of Medi-Cal fraud). This overlaps somewhat with anti-waste rhetoric but stays within an expansionist framework.
Bureaucracy over care: Becerra’s strategies center on expanding coverage and protections (for example, Medi-Cal inclusivity), regulatory enforcement against perceived profiteers (pharma and others), and equity and prevention investments. These articles show how such an environment, coupled with board overreach and PA hurdles in state programs, perpetuates shortages, delays, and undertreatment rather than resolving them. Single-payer leanings risk amplifying bureaucracy without fixing root causes like MBC tactics or reimbursement failures.

Status quo impact: The articles explicitly document how California’s current system (heavy regulation, high costs and taxes, one-party dominance without bold reform) is causing severe physician shortages, burnout, delayed and chronic pain mismanagement, consolidation, higher litigation and admin costs, medical debt, and lagging outcomes despite high spending. This unsustainable trajectory risks further access declines, especially under federal pressures, validating calls for structural change beyond incremental protections.

Real outcomes would hinge on implementation amid Democratic legislative majorities. Overall, the articles serve as a data-rich warning that without addressing bureaucracy and provider sustainability, expansions alone won’t deliver affordable, high-quality care.

Kayvan Haddadan is a physiatrist and pain management physician, and president and medical director of Advanced Pain Diagnostic & Solutions, a multidisciplinary pain management practice in California that he founded in 2012. A physician and surgeon licensed by the Medical Board of California, he is double board-certified in pain medicine and physical medicine and rehabilitation. He is also certified in controlled substance registration through the DEA and serves as a qualified medical examiner through California’s Department of Industrial Relations Division of Workers’ Compensation.

Dr. Haddadan earned his Bachelor of Science degree from the College of Alborz in Tehran, Iran, and his medical degree from Shahid Beheshti University of Medical Sciences. He later received his Educational Commission for Foreign Medical Graduates certification in Philadelphia, completed an internship in medical surgery at Loyola University Medical Center’s Stritch School of Medicine in Illinois, and finished his residency in physical medicine and rehabilitation at the same institution. He completed his fellowship in pain medicine at California Pacific Medical Center’s Pacific Pain Treatment Center and also trained in medical acupuncture for physicians at the University of California, Los Angeles David Geffen School of Medicine.

Dr. Haddadan has contributed to 29 research publications across multiple specialties, including pain management, cardiology, pulmonology, endocrinology, gastroenterology, and infectious disease. His work has examined topics such as hyperlipidemia in high cardiovascular risk patients, hyperuricemia and gout management, type 2 diabetes and hypertension, chronic obstructive pulmonary disease and asthma therapies, influenza treatment, irritable bowel syndrome, and opioid related complications in chronic pain care. His research has also included clinical outcome studies in spinal cord stimulation and award-winning presentations on neuropathic pain management and neuromuscular disorders.